These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

211 related items for PubMed ID: 12553015

  • 1. Anti-tumor and anti-vascular effects of the novel tubulin-binding agent combretastatin A-1 phosphate.
    Holwell SE, Cooper PA, Thompson MJ, Pettit GR, Lippert LW, Martin SW, Bibby MC.
    Anticancer Res; 2002; 22(6C):3933-40. PubMed ID: 12553015
    [Abstract] [Full Text] [Related]

  • 2. Combretastatin A-1 phosphate a novel tubulin-binding agent with in vivo anti vascular effects in experimental tumours.
    Holwell SE, Cooper PA, Grosios K, Lippert JW, Pettit GR, Shnyder SD, Bibby MC.
    Anticancer Res; 2002; 22(2A):707-11. PubMed ID: 12017147
    [Abstract] [Full Text] [Related]

  • 3. Eradication of colorectal xenografts by combined radioimmunotherapy and combretastatin a-4 3-O-phosphate.
    Pedley RB, Hill SA, Boxer GM, Flynn AA, Boden R, Watson R, Dearling J, Chaplin DJ, Begent RH.
    Cancer Res; 2001 Jun 15; 61(12):4716-22. PubMed ID: 11406542
    [Abstract] [Full Text] [Related]

  • 4. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature.
    Dark GG, Hill SA, Prise VE, Tozer GM, Pettit GR, Chaplin DJ.
    Cancer Res; 1997 May 15; 57(10):1829-34. PubMed ID: 9157969
    [Abstract] [Full Text] [Related]

  • 5. Combination chemotherapy with combretastatin A-4 phosphate and 5-fluorouracil in an experimental murine colon adenocarcinoma.
    Grosios K, Loadman PM, Swaine DJ, Pettit GR, Bibby MC.
    Anticancer Res; 2000 May 15; 20(1A):229-33. PubMed ID: 10769660
    [Abstract] [Full Text] [Related]

  • 6. In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug.
    Grosios K, Holwell SE, McGown AT, Pettit GR, Bibby MC.
    Br J Cancer; 1999 Dec 15; 81(8):1318-27. PubMed ID: 10604728
    [Abstract] [Full Text] [Related]

  • 7. Oxi4503, a novel vascular targeting agent: effects on blood flow and antitumor activity in comparison to combretastatin A-4 phosphate.
    Hua J, Sheng Y, Pinney KG, Garner CM, Kane RR, Prezioso JA, Pettit GR, Chaplin DJ, Edvardsen K.
    Anticancer Res; 2003 Dec 15; 23(2B):1433-40. PubMed ID: 12820406
    [Abstract] [Full Text] [Related]

  • 8. ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature.
    Davis PD, Dougherty GJ, Blakey DC, Galbraith SM, Tozer GM, Holder AL, Naylor MA, Nolan J, Stratford MR, Chaplin DJ, Hill SA.
    Cancer Res; 2002 Dec 15; 62(24):7247-53. PubMed ID: 12499266
    [Abstract] [Full Text] [Related]

  • 9. Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo.
    Galbraith SM, Chaplin DJ, Lee F, Stratford MR, Locke RJ, Vojnovic B, Tozer GM.
    Anticancer Res; 2001 Dec 15; 21(1A):93-102. PubMed ID: 11299795
    [Abstract] [Full Text] [Related]

  • 10. Anti-vascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate.
    Chaplin DJ, Pettit GR, Hill SA.
    Anticancer Res; 1999 Dec 15; 19(1A):189-95. PubMed ID: 10226542
    [Abstract] [Full Text] [Related]

  • 11. Induction of apoptosis in proliferating human endothelial cells by the tumor-specific antiangiogenesis agent combretastatin A-4.
    Iyer S, Chaplin DJ, Rosenthal DS, Boulares AH, Li LY, Smulson ME.
    Cancer Res; 1998 Oct 15; 58(20):4510-4. PubMed ID: 9788591
    [Abstract] [Full Text] [Related]

  • 12. Abilities of 3,4-diarylfuran-2-one analogs of combretastatin A-4 to inhibit both proliferation of tumor cell lines and growth of relevant tumors in nude mice.
    Sun L, Vasilevich NI, Fuselier JA, Coy DH.
    Anticancer Res; 2004 Oct 15; 24(1):179-86. PubMed ID: 15015595
    [Abstract] [Full Text] [Related]

  • 13. Preclinical evaluation of the antitumour activity of the novel vascular targeting agent Oxi 4503.
    Hill SA, Toze GM, Pettit GR, Chaplin DJ.
    Anticancer Res; 2002 Oct 15; 22(3):1453-8. PubMed ID: 12168822
    [Abstract] [Full Text] [Related]

  • 14. Antineoplastic agents. 379. Synthesis of phenstatin phosphate.
    Pettit GR, Toki B, Herald DL, Verdier-Pinard P, Boyd MR, Hamel E, Pettit RK.
    J Med Chem; 1998 May 07; 41(10):1688-95. PubMed ID: 9572894
    [Abstract] [Full Text] [Related]

  • 15. The vascular targeting agent combretastatin A-4-phosphate induces neutrophil recruitment to endothelial cells in vitro.
    Brooks AC, Kanthou C, Cook IH, Tozer GM, Barber PR, Vojnovic B, Nash GB, Parkins CS.
    Anticancer Res; 2003 May 07; 23(4):3199-206. PubMed ID: 12926054
    [Abstract] [Full Text] [Related]

  • 16. Antineoplastic agents 429. Syntheses of the combretastatin A-1 and combretastatin B-1 prodrugs.
    Pettit GR, Lippert JW.
    Anticancer Drug Des; 2000 Jun 07; 15(3):203-16. PubMed ID: 11049088
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Combretastatin A-1 phosphate potentiates the antitumour activity of cisplatin in a murine adenocarcinoma model.
    Shnyder SD, Cooper PA, Pettit GR, Lippert JW, Bibby MC.
    Anticancer Res; 2003 Jun 07; 23(2B):1619-23. PubMed ID: 12820431
    [Abstract] [Full Text] [Related]

  • 19. Novel combretastatin analogues effective against murine solid tumors: design and structure-activity relationships.
    Ohsumi K, Nakagawa R, Fukuda Y, Hatanaka T, Morinaga Y, Nihei Y, Ohishi K, Suga Y, Akiyama Y, Tsuji T.
    J Med Chem; 1998 Jul 30; 41(16):3022-32. PubMed ID: 9685242
    [Abstract] [Full Text] [Related]

  • 20. Determinants of anti-vascular action by combretastatin A-4 phosphate: role of nitric oxide.
    Parkins CS, Holder AL, Hill SA, Chaplin DJ, Tozer GM.
    Br J Cancer; 2000 Sep 30; 83(6):811-6. PubMed ID: 10952787
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.